Khiron Life Sciences Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
For the nine months, revenue was CAD 12.5 million compared to CAD 9.16 million a year ago. Net loss was CAD 11.16 million compared to CAD 13.63 million a year ago. Basic loss per share from continuing operations was CAD 0.06 compared to CAD 0.09 a year ago. Diluted loss per share from continuing operations was CAD 0.06 compared to CAD 0.09 a year ago.